Analyst Ratings For Akcea Therapeutics Inc (NASDAQ:AKCA)
Today, Stifel Nicolaus raised its price target on Akcea Therapeutics Inc (NASDAQ:AKCA) to $31.00 per share.
There are 3 Hold Ratings, 3 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Akcea Therapeutics Inc (NASDAQ:AKCA) is Buy with a consensus target price of $40.50 per share, a potential 17.29% upside.
Some recent analyst ratings include
- 9/18/2018-Akcea Therapeutics Inc (NASDAQ:AKCA) has coverage initiated with a Buy ➝ Buy rating and $45.00 price target
- 9/2/2018-Akcea Therapeutics Inc (NASDAQ:AKCA) had its Hold rating reiterated by Cowen
- 8/8/2018-Akcea Therapeutics Inc (NASDAQ:AKCA) gets downgraded to Hold by UBS Group
Recent Insider Trading Activity For Akcea Therapeutics Inc (NASDAQ:AKCA)
Akcea Therapeutics Inc (NASDAQ:AKCA) has insider ownership of 3.88% and institutional ownership of 26.58%.
- On 4/17/2018 Ionis Pharmaceuticals Inc, Major Shareholder, bought 10,666,666 with an average share price of $18.75 per share and the total transaction amounting to $199,999,987.50.
- On 7/19/2017 Ionis Pharmaceuticals Inc, Major Shareholder, bought 3,125,000 with an average share price of $8.00 per share and the total transaction amounting to $25,000,000.00.
Recent Trading Activity for Akcea Therapeutics Inc (NASDAQ:AKCA)
Shares of Akcea Therapeutics Inc closed the previous trading session at 34,98 up +1,90 5,74 % with 33.48 shares trading hands.
